Vasopressin does not raise cardiac enzymes following cardiac surgery: a randomized double-blind clinical trial

What Was Tested

This randomized controlled trial paper looks at Vasopressin.

The aim of this study was to investigate the relationship between intraoperative vasopressin infusion and postoperative cardiac enzymes.

Who Took Part

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.

One hundred consecutive patients undergoing cardiac surgery with or without cardiopulmonary bypass.

The study was approved by the Institutional Review Board, and patients provided informed consent to participate.

How the Study Was Run

In design terms this was a randomized and double-blind study.

The participants were allocated by chance, so the Vasopressin group and the comparison group should start out alike.

As a double-blind Vasopressin study, the assignments were hidden from both participants and investigators until the end.

A prospective, double-blind, randomized, controlled study.

A single tertiary cardiac center.

Patients were randomized by computer into 2 equal groups: Vasopressin or control.

The drug was administered continually during surgery while patients needed catecholamines.

The intervention was discontinued upon admission to the intensive care unit when information regarding the true character of the drug was reported to the doctor in charge of patients in the intensive care unit by one of the investigators.

What Was Measured

Primary outcomes were CK-MB and troponin T levels measured at 0, 6, and 12 hours postoperatively.

Topics PubMed links to this paper include Cardiac Surgical Procedures, Perioperative Care, Postoperative Complications, Troponin T, Vasoconstrictor Agents and Vasopressins.

Author keywords: cardiac enzymes, cardiac surgery and vasoplegia.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vasopressin.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2015 (Journal of cardiothoracic and vascular anesthesia), a journal based in United States.

More context: the Vasopressin compound page, all human trials.